Takeda's $4B immunology drug achieves first Phase 3 successes
武田制药价值40亿美元的免疫学药物首次在三期临床试验中取得成功

Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off.
早期回报显示，武田制药斥资40亿美元的免疫学押注似乎正在奏效。